Hanoi, Vietnam- Media Volunteer Service News Wire April 14, 20125 -With Joel F. Habener professor, Jens Juul Holst with world -renowned scientists. Professor Daniel Drucker at the University of Toronto and Professor Svetlana Mojsov and Lunenfeld-Tanenbaum Research Institute discovered the role of peptide-1 (GLP-1) such as glucagon, leading to a treatment of lives to diabetes and obese people. It stimulates emerging applications for designation. This breakthrough innovation has been significantly recognized for the GLP-1 research group, and has won the famous 2023 Vinfute Special Prize for innovators with excellent results in emerging fields and the 2025 Life Science Award.
Professor Daniel Drucker, 2023 Vinfute Special Prize Winners continue to be recognized for the 2025 Special Prize winners for innovators who have achieved outstanding results in emerging fields.
In this interview, he reflects the impact on further research on Vinfute Prize and the challenges and prospects of expanding GLP-1 accessibility. As global scientific recognition continues to develop, he shares his insight into the important role of initiatives, such as the Vinfute Award, which inspires the next -generation scientists.
Vinfute: Recognition teaRansformative SCines
2023 Vinfute Prize is the first major international science and technology to recognize and respect scientists who have found the role of GLP-1. Following the Vinfute Prize, the GLP-1 research group was continuously recognized for many other famous praise, including the listing among the most influential people of 100 in 2024.
Reflecting this, Professor Drucker expressed his deepest gratitude, pointing out that this image provides valuable support to promote the boundaries of scientific discoveries.
“The Vinfute award is prominent, helping people who recognize GLP-1 science as a recipient help to improve their global understanding of how to change their health care.He emphasized.
The 2024 Vinfute Prize continued to promise to recognize influential development and honored innovators in the field of biotechnology to develop automotive T cell therapy for cancer and other diseases. According to Professor Drucker, this innovation is “Amazing example of how to revolutionize the treatment of cancer type with many immune science. “
“Respecting AI and CAR T cell therapy, the trend I observed is consistent with other international awards, and at the same time or in a few years, a similar innovative topic is celebrated. This alignment strengthens the importance of this innovation.“Professor Drucker commented.
Among the youngest international science and technology in the fifth year, Vinfute Prize has been steadily established its importance and reputation due to the increase in honor of honorable international awards, especially the Nobel Prize. Dr. Katalin Karikó and Dr. Dr. Dr. Dr. Dr. Drew Weissman (2021 Vinfute Grand Prize and 2023 Nobel Prize) 2024 NOFF. Vinfute Grand Award and 2024 Nobel Physics Prize).
“Despite being a relatively new prize, Vinfute Prize has been doing excellent work to emphasize high quality science. Recent recognition of AI, which is consistent with the recent Nobel Prize, emphasizes the transformational impact on the numerous aspects of society.“Professor Drucker said.”So I think Vinfute Prize Council has a finger in the cutting edge of science in many areas.. “
2024 was a groundbreaking year of GLP-1 research, and there are some interesting clinical trials that show the benefits of expanding beyond obesity, including heart disease, obstructive sleep apnea and knee osteoarthritis patients. Professor Drucker also implied the initial promising results of patients with metabolic diseases, and the results of the influence of GLP-1 on Alzheimer’s disease were expected.
“Continuous waves of new discovery will provide deeper insight into the potential of GLP-1-based therapy.Professor Drucker mentioned that each research will contribute to the purification of our understanding of this science.
In addition, Professor Drucker emphasized the neurological effects and potential clinical applications of GLP-1 in dealing with mental health, including anxiety, depression and obsessive behavior. He noted that the early stage test with a small patient group, which investigates the potential of GLP-1 for the reduction of craving and the treatment of addiction-related disorders, has calculated promising initial results.
“Some academic research centers are actively studying the effects of GLP-1 on substance disorders, and major pharmaceutical companies, such as ELI Lilly and Novo Nordisk, have started clinical trials to further explore these applications.. “Professor Drucker shared.”It will take 12 to 18 months to get a clear picture of whether this drug can be clinically effective to reduce or quit the use of materials.. “
Professor Drucker also emphasized a powerful study that shows the interaction between GLP-1 and the brain and expands beyond appetite control, suggesting various therapeutic applications.
“Those who have substance disorders, including alcohol, nicotine, canabinoids and opioids, are undergoing tests ongoing with existing medicines are not always effective.. “He was elaborate.”We are in the process of Alzheimer’s disease, which is expected to conclude by the end of 2025.. This investigation will greatly improve the understanding of the neurological effects of GLP-1 and potential clinical applications..“
Overcome the barrier to maximize the shock
Despite the global excitement of the “Ozempic era,” there are many challenges that interfere with a wide range of influence on GLP-1 pharmaceuticals. This includes dependence on the current expensive and limited accessibility of processing, mainly the dependence on two major drug options (semaglucide and tir fade), and the dependence on the actual limit of refrigeration and pen -based delivery to most preparations as pointed out by Professor Drucker.
“The core priority is to ensure that the democratization of these treatments can be accessed by everyone who can benefit from them. To achieve this, we are studying small molecular drugs that are easy to manufacture and need to be cheaper.He explained.
Professor Drucker predicts that as competition in the GLP-1 market increases, prices will be lowered and the development of the latest version, which is easy to use once a month, will improve millions of access and convenience around the world.
“Most initial launches have occurred in countries with well -established medical and repayment systems. Although the manufacturing capacity is expanding enough to increase its availability, the cost remains an important barrier.“He not only improves efficacy in areas such as weight loss and cardiovascular health, but also emphasizes the need for developing these medicines so that patients around the world are more convenient, inexpensive and more approached.
Another major task confirmed by Professor Drucker is to determine the appropriate dose to extend the treatment of GLP-1 beyond diabetes and obesity. Effective doses for weight loss may not be suitable for other disorders such as Parkinson’s bottle and Alzheimer’s alcohol disorder, anxiety or depression, but it takes time and further investigation to understand the capacity-reaction relationship for these conditions.
In addition, research is underway to reduce side effects, and GLP-1 treatment is safer and more comfortable to the patient. Professor Drucker became sophisticated. “One main strategy is to start a very low dose patient and gradually increases to minimize side effects. In addition, some companies are studying methods to reduce additional side effects, such as developing co -formation anti -NAUSEA compounds, to improve the tolerability.. “
Future research on GLP-1 therapy suggests a number of possibilities. However, translation to clinical applications in the study of neurochrogenic and disability disorders still suggest requirements that are not satisfied with lack of evidence of progress. According to Professor Drucker, clinical trials are in progress, and you can get valuable insights within the next 12 to 24 months with regard to the potential extension of GLP-1 therapy, from glucose regulation to complex disorders of the central nervous system.
He confirmed. “The key is to understand how to effectively participate in the brain, to understand what areas can respond to GLP-1 signals, and how to optimize the communication.. “
In conclusion, Professor Drucker emphasized the promising modern scientific research environment, emphasizing the important need for the next generation to accept science and pursue research career. In this context, the 2023 Vinfute Special Prize Laureate praised the Vinfute Award as a valuable contribution to motivating individuals in the scientific community and to participate in the younger generation in science.
“When we visited Vietnam, we met many young scientists, and I was impressed by Vinfute’s strong efforts to inspire and connect with them. It is recommended that Vinfute will continue and expand this effort because investment in young talent is the key to the future full of innovation.“He said.
Hashtag: #VINFUTURE
https://vinfuteprize.org/vinfute-prize-nomination/The publisher is only responsible for the contents of this presentation.
Vinfute
Founded on December 20, 2020, Vinfute Foundation is a non -profit organization co -founded by billionaire Pham Nhat Vuong and his wife Pham Thu Huong. The core activity of the Foundation is awarded the annual Vinfute Prize and recognizes innovative science and technological innovations that can bring significantly positive changes to the lives of millions of people around the world.
The nomination period of 2025 Vinfute Prize is closed at 2 pm on April 17, 2025 (Vietnam, GMT+7). Submit the name here. https://vinfuteprize.org/vinfute-prize-nomination/. The Vinfute Nominee Recognition Program will be honored by the outstanding nominee. Vinfute Prize consists of four prestigious phases every year. The most respected thing is one of the world’s largest annual statues of $ 3 million. In addition, there are three special awards of $ 500,000, each, especially in response to respect for innovators with outstanding achievements in the field of innovators and emerging areas of women, developing countries.
